Overview

Monogenic Obesity is usually accompanied by abnormal function of key proteins in appetite regulation and energy metabolism pathways, which causes severe weight gain. It can be categorized into syndromic monogenic obesity and non-syndromic monogenic obesity. Accurate diagnosis of non-syndromic monogenic obesity is essential for assessing obesity risk and developing personalized interventions.

Unlocking the Genetic Roots of Monogenic Obesity

Protheragen provides a non-syndromic monogenic Obesity Panel Testing service to meet the demand for accurate obesity diagnosis. Based on advanced sequencing technology, we provide comprehensive and in-depth analysis of multiple core genes known to be closely associated with non-syndromic monogenic obesity.

Sample Collection and Processing

Upon receipt of the samples, we perform initial processing and DNA extraction. Through multi-dimensional quality control, the concentration, purity, and integrity of the DNA obtained meet the requirements for subsequent sequencing.

Sequencing

The sequence and copy number of non-syndromic single-gene obesity-related genes are examined using next-generation sequencing (NGS), Sanger sequencing, or other gene sequencing technologies.

Bioinformatics Analysis

We start by preprocessing the raw sequencing data and aligning the sequences to the reference genome. Leveraging powerful bioinformatics tools, we then pinpoint genetic variants linked to obesity and conduct an in-depth analysis of their predicted biological impact. All results are compiled into a detailed report, which covers the identified genetic variants, their clinical interpretation, implications for risk, and other essential scientific context, all presented in a clear, comprehensive, and easy-to-understand format.

Workflow

Applications

• The non-syndromic monogenic obesity panel test is used for in-depth genetic characterization to provide insight into the genome and useful information for detailed assessment of obesity risk.
• The non-syndromic monogenic obesity panel test plays an important role in developing preventive measures based on the risk of obesity in order to reduce the likelihood of developing obesity and related metabolic diseases in the future.
• The non-syndromic monogenic obesity panel test is used to analyze genetic factors in weight management and provides useful information for developing targeted intervention strategies.

Advantages

• Our panel design focuses on non-syndromic monogenic obesity and contains core and meaningful genes for in-depth analysis.
• High-standard sequencing platforms and rigorous experimental procedures are used to ensure the accuracy and reliability of the assay data.
• Our bioinformatics team utilizes rich database resources for analysis to ensure the accuracy of variant analysis.

One-stop Anti-obesity Research Support

We also provide one-stop anti-obesity research services, which include the following:

Publication Data

Frequently Asked Questions

1. What is non-syndromic monogenic obesity?

   Non-syndromic monogenic obesity is thought to usually result from defects in the leptin-melanocortin pathway, which plays a crucial role in energy homeostasis. Most of the genes involved in this pathway have been extensively studied, including MC4R, POMC, SIM1, PCSK1, and LEPR. Signals from peripheral tissues are processed in the hypothalamus and regulate food intake, ultimately affecting weight change.

2. What are the representative genes contained in the non-syndromic monogenic obesity panel?
   • MC4R: MC4R is an important receptor in the leptin-melanocortin signaling pathway, which regulates appetite and energy balance. Abnormalities in MC4R lead to impaired receptor function, causing obesity.
   • LEPR: LEPR is a leptin receptor gene, and mutations in LEPR result in the failure of leptin signaling, which can lead to hyperphagia and obesity.
   • PCSK1: PCSK1 is an enzyme that cleaves peptide precursors such as pro-opiomelanocortin (POMC) to produce functional neuropeptides. PCSK1 defects affect the production of many hormones and neuropeptides, leading to obesity and endocrine dysfunction.
   • Other types

Protheragen utilizes cutting-edge sequencing platforms and focuses on providing highly accurate obesity-related genetic analysis services. By screening for genetic variants that are strongly associated with obesity, in order to provide exclusive insight into genetic information. To experience the value of this service, please contact us today!

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

• Bardet-Biedl Syndrome Panel Test Service
• Comprehensive Monogenic Obesity Panel Test Service
• Diabetes-Obesity NGS Panel Test Service